Crossmark

Antibody responses against influenza A decline with successive years of annual influenza vaccination

Crossref DOI link: https://doi.org/10.1038/s41541-024-01057-x

Published Online: 2025-01-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sullivan, Sheena G. https://orcid.org/0000-0002-0856-0294
Khvorov, Arseniy

Carolan, Louise

Dowson, Leslie

Hadiprodjo, A. Jessica

Sánchez-Ovando, Stephany

Liu, Yi https://orcid.org/0000-0002-2157-8368
Leung, Vivian K. Y.

Hodgson, David

Blyth, Christopher C.

Macnish, Marion

Cheng, Allen C.

Haugenauer, Michelle

Clark, Julia

Dougherty, Sonia

Macartney, Kristine https://orcid.org/0000-0002-4675-0232
Koirala, Archana

Khatami, Ameneh https://orcid.org/0000-0001-9114-6694
Jadhav, Ajay

Marshall, Helen

Riley, Kathryn E.

Wark, Peter A. B.

Delahunty, Catherine

Subbarao, Kanta https://orcid.org/0000-0003-1713-3056
Kucharski, Adam J.

Fox, Annette
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI141534, R01AI141534, R01AI141534, R01AI141534, R01AI141534, R01AI141534, R01AI141534, R01AI141534, R01AI141534, R01AI141534)
License Information

Text and Data Mining valid from 2025-01-17

Version of Record valid from 2025-01-17
More Information

Article History

Received: 3 August 2024

Accepted: 19 December 2024

First Online: 17 January 2025

Competing interests

: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AF, AK, SGS report financial support was provided by National Institutes of Health. AF reports funding/grants from Sanofi Aventis, France. HM reports funding/grants from bioCSL, Pfizer Inc, GlaxoSmithKline. PW reports funding/grants from GlaxoSmithKline Inc, Krystal Biotech, Inc. Vertex Pharmaceuticals, Sanofi. SGS reports consulting for Pfizer Inc, Moderna Inc, Seqirus, Evo Health and Novavax. ACC, CCB are previous Chairs of the Australian Technical Advisory Group on Immunisation (ATAGI). The opinions in this study may not reflect the policy of ATAGI or the Australian Government regarding influenza vaccines.

: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol and protocol addendums for follow-up of COVID-19 vaccinations and SARS-CoV-2 infections were approved by The Royal Melbourne Hospital Human Research Ethics Committee (HREC/54245/MH-2019).

: Written informed consent was obtained from all individuals who participated in the study.

Document is current

Any future updates will be listed below